| Literature DB >> 28637794 |
Katarzyna Malenczyk1,2, Fatima Girach1, Edit Szodorai1, Petter Storm3, Åsa Segerstolpe4, Giuseppe Tortoriello2, Robert Schnell5, Jan Mulder6, Roman A Romanov1,2, Erzsébet Borók7, Fabiana Piscitelli8, Vincenzo Di Marzo8, Gábor Szabó9, Rickard Sandberg4, Stefan Kubicek10, Gert Lubec11, Tomas Hökfelt2, Ludwig Wagner12, Leif Groop3, Tibor Harkany13,2.
Abstract
Ca2+-sensor proteins are generally implicated in insulin release through SNARE interactions. Here, secretagogin, whose expression in human pancreatic islets correlates with their insulin content and the incidence of type 2 diabetes, is shown to orchestrate an unexpectedly distinct mechanism. Single-cell RNA-seq reveals retained expression of the TRP family members in β-cells from diabetic donors. Amongst these, pharmacological probing identifies Ca2+-permeable transient receptor potential vanilloid type 1 channels (TRPV1) as potent inducers of secretagogin expression through recruitment of Sp1 transcription factors. Accordingly, agonist stimulation of TRPV1s fails to rescue insulin release from pancreatic islets of glucose intolerant secretagogin knock-out(-/-) mice. However, instead of merely impinging on the SNARE machinery, reduced insulin availability in secretagogin-/- mice is due to β-cell loss, which is underpinned by the collapse of protein folding and deregulation of secretagogin-dependent USP9X deubiquitinase activity. Therefore, and considering the desensitization of TRPV1s in diabetic pancreata, a TRPV1-to-secretagogin regulatory axis seems critical to maintain the structural integrity and signal competence of β-cells.Entities:
Keywords: Ca2+ signalling; diabetes; endocannabinoid; exocytosis; β‐cell
Mesh:
Substances:
Year: 2017 PMID: 28637794 PMCID: PMC5510001 DOI: 10.15252/embj.201695347
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598